<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075695</url>
  </required_header>
  <id_info>
    <org_study_id>UWFARVO</org_study_id>
    <nct_id>NCT04075695</nct_id>
  </id_info>
  <brief_title>Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion</brief_title>
  <acronym>UWFARVO</acronym>
  <official_title>Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renmin Hospital of Wuhan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The changes of ischemic index and vascular leakage index, and the effect on macular edema and
      neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography
      (UWFA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the ischemic index and vascular leakage index, and the effect on macular edema
      and neovascularization in retinal vein occlusion will be evaluated by ultra-wide field
      fluorescence angiography (UWFA). UWFA has a wider range than conventional angiography, and
      can clearly observe the peripheral retina. The purpose of this study is to quantitatively
      analyze these changes and investigate the effect on macular edema and neovascularization
      secondary to retinal vein occlusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">August 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in non-perfused areas in different retinal area</measure>
    <time_frame>Baseline and1，2，3，6，9and 12 months</time_frame>
    <description>Change in non-perfused areas in different retinal area from Baseline to 1，2，3，6，9and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity</measure>
    <time_frame>Baseline and1，2， 3, 6, 9 and 12 months</time_frame>
    <description>Change in best corrected visual acuity from Baseline to 1，2，3，6，9and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central macular thickness</measure>
    <time_frame>Baseline and1，2， 3, 6, 9 and 12 months</time_frame>
    <description>Change in central macular thickness from Baseline to 1，2，3，6，9and 12 months</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 18 years or more

          2. Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema

          3. Duration of RVO not more than 4 months

          4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion
             date) which completely resolved (normalization of visual acuity and fundus
             examination) and who experienced a recurrence of RVO are also considered naive

          5. Patient who agrees to participate to the study and who has given his/her written,
             informed consent

        Exclusion Criteria:

          1. Patient with another retinal disease in the study eye: diabetic retinopathy,
             maculopathy of any cause (age-related macular degeneration, epimacular membrane,
             myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely
             affecting vision and/or requiring surgical treatment during the 24 months study period

          2. Active or suspected ocular or periocular infection

          3. Active severe intraocular inflammation

          4. RVO complicated with neovascularization

          5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or
             photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study
             eye

          6. Patient already included in the study for the treatment of the fellow eye

          7. Pregnant or breastfeeding woman

          8. Lack of effective contraception for women of childbearing age

          9. Patient taking part in an interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renmin Hospital of Wuhan University</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renmin Hospital of Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CZ Chen, PHD</last_name>
    <phone>+86 13072765173</phone>
    <email>whuchenchzh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>XL Wang</last_name>
    <phone>+86 13117192316</phone>
    <email>wangxl0807@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CZ Chen, PHD</last_name>
      <phone>+86 13072765173</phone>
      <email>whuchenchzh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>XL Wang</last_name>
      <phone>+86 13117192316</phone>
      <email>wangxl0807@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Renmin Hospital of Wuhan University</investigator_affiliation>
    <investigator_full_name>Changzheng Chen</investigator_full_name>
    <investigator_title>Chief of Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>ischemic index</keyword>
  <keyword>Ultra-wide field fundus fluorescein angiography</keyword>
  <keyword>vascular leakage index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

